Peloton Therapeutics Overview
- Founded
-
2011
- Status
-
Private
- Employees
-
64
- Latest Deal Type
-
M&A
- Latest Deal Amount
-
$2.35B
- Investors
-
1
Peloton Therapeutics General Information
Description
Peloton Therapeutics Inc is a clinical stage biopharmaceutical company focused on translating novel scientific insights into medicines for patients with cancer and other debilitating or life-threatening conditions. It is focused on targeting HIF-2a, a transcription factor which was thought to be intractable using a small molecule. The company's drug candidate, PT2977, has shown clinical proof of concept in patients with advanced or metastatic clear cell renal cell carcinoma.
Contact Information
Website
www.pelotontherapeutics.com
Formerly Known As
Damascus Pharmaceuticals
Ownership Status
Privately Held (backing)
Financing Status
Formerly VC-backed
Primary Industry
Pharmaceuticals
Other Industries
Drug Discovery
Primary Office
- 2330 Inwood Road
- Suite 226
- Dallas, TX 75235
- United States
+1 (972) 000-0000
Peloton Therapeutics Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 9. Merger/Acquisition | 11-Jul-2019 | $2.35B | 00000 | 00.000 | Completed | Clinical Trials - Phase 2 |
| 8. IPO | 26-Apr-2019 | 00000 | 00000 | Cancelled | Clinical Trials - Phase 2 | |
| 7. Later Stage VC (Series E) | 20-Feb-2019 | 00000 | 00000 | 00000 | Completed | Generating Revenue |
| 6. Later Stage VC (Series D) | 14-Mar-2017 | 000.00 | 00000 | 00000 | Completed | Clinical Trials - Phase 2 |
| 5. Grant | 05-Aug-2016 | 0000 | 000.00 | Completed | Clinical Trials - Phase 2 | |
| 4. Later Stage VC (Series C) | 05-Nov-2014 | 000.00 | 000.00 | 00000 | Completed | Clinical Trials - Phase 1 |
| 3. Early Stage VC (Series B) | 18-Dec-2013 | 000.00 | 000.00 | 000.00 | Completed | Startup |
| 2. Grant | $11M | $18M | Completed | Startup | ||
| 1. Early Stage VC (Series A) | 27-Jul-2011 | $18M | $18M | 0000 | Completed | Startup |
Peloton Therapeutics Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate ($) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series E | 00,000,000 | 00.000000 | 00.0 | 00.00 | 00.00 | 00 | 00.00 | 000 |
| Series D | 00,000,000 | 00.000000 | 00.00 | 00.00 | 00.00 | 00 | 00.00 | 00.000 |
| Series C | 00,000,000 | 00.000000 | 00.00 | 00.00 | 00.00 | 00 | 00.00 | 00.000 |
| Series B | 10,080,000 | $0.000100 | $0.1 | $1.25 | $1.25 | 1x | $1.25 | 7.68% |
| Series A | 17,100,000 | $0.000100 | $0.08 | $1 | $1 | 1x | $1 | 13.03% |
Peloton Therapeutics Comparisons
Description
Primary
Industry
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Financing
Details
Peloton Therapeutics Inc is a clinical stage biopharmaceutical company focused on translating novel scientific insights
Pharmaceuticals
Dallas, TX
64
As of 2019
00000
0.000
0000-00-00
000000&0
00000
000-00
or incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis no
0000 000000000
Vienna, VA
00
As of 0000
000.00
000000000
000.00
00000
veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo
0000 000000000
Cambridge, MA
00
As of 0000
00000
0000
0000-00-00
000000&0
00000
Add Comparison
Peloton Therapeutics Competitors (89)
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| CEL-SCI | Corporate Backed or Acquired | Vienna, VA | 00 | 000.00 | 000000000 | 000.00 |
| 00000 000 | Formerly VC-backed | Cambridge, MA | 00 | 00000 | 000000&0 | 00000 |
| 000000000 00000000 | Formerly VC-backed | San Francisco, CA | 000 | 00000 | 000000&0 | 00000 |
| 000000000 00000000 | Formerly VC-backed | San Diego, CA | 000 | 00000 | 000000000 | 00000 |
| 0000000 | Formerly PE-Backed | Cambridge, MA | 0000 | 00.000 | 00000000000 | 00.000 |
Peloton Therapeutics Patents
Peloton Therapeutics Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| US-20220081407-A1 | Methods of preparing substituted indanes | Inactive | 11-Sep-2020 | 0000000000 | |
| EP-3953331-A4 | Pyrazolesulfonamides as antitumor agents | Pending | 10-Apr-2019 | 0000000000 | |
| US-20220162193-A1 | Pyrazolesulfonamides as antitumor agents | Pending | 10-Apr-2019 | 0000000000 | |
| EP-3953331-A1 | Pyrazolesulfonamides as antitumor agents | Pending | 10-Apr-2019 | 0000000000 | |
| CA-3117563-A1 | Solid dispersions and pharmaceutical compositions comprising a substituted indane and methods for the preparation and use thereof | Pending | 30-Oct-2018 | C07C317/22 |
Peloton Therapeutics Executive Team (18)
| Name | Title | Board Seat | Contact Info |
|---|---|---|---|
| Zhaodan Cao Ph.D | Director, Biology | ||
| Peter Stengel Ph.D | Director, Chemical Development | ||
| John Josey Ph.D | President, Chief Executive Officer & Board Member | ||
| Alan Musso | Chief Financial Officer | ||
| James Tananbaum MD | Advisor |
Peloton Therapeutics Board Members (14)
| Name | Representing | Role | Since |
|---|---|---|---|
| Brett Ringle JD | Remeditex Ventures | Board Member | 000 0000 |
| John Josey Ph.D | Self | President, Chief Executive Officer & Board Member | 000 0000 |
Peloton Therapeutics Signals
Growth Rate
0.80%
Weekly
Growth
Growth
Weekly Growth
0.80%, 93rd %
-35.5%.
530%
Size Multiple
219x
Median
Size Multiple
219x, 100th %ile
0.00x
0.95x.
413Kx
Key Data Points
Twitter Followers
5.5k
Similarweb Unique Visitors
15.0K
Majestic Referring Domains
314
Peloton Therapeutics Investors (1)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|---|---|---|---|---|
| Gershon Capital | Venture Capital | Minority | 000 0000 | 000000 0 |